Company profile
Solid Biosciences Inc.
NASDAQ: SLDB · Healthcare · Biotechnology
#656 of 1,422 Healthcare companies by revenuebottom-quartile growth
EA Score
41DFH 42DQ 34GM —SS 63
v0.1 · 55/100 weight · provisional
↑ Altman-Z, balance-sheet leverage · ↓ operating margin, net margin
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$174.3M
Employees
121
as of 2026-08-10
Market cap
$826.0M
as of 2026-08-10
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$8.1M$8.1M2022
Net income-$174.3M-$174.3M2025
Operating income-$179.2M-$179.2M2025
Total assets$232.5M$232.5M2025
Liabilities$52.5M$52.5M2025
Equity$180.0M$180.0M2025
Revenue trend
FY2018 – FY2022 · USD
FY18
FY19
FY19
FY19
FY19
FY20
FY21
FY22
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Solid Biosciences Inc.’s revenue?
Solid Biosciences Inc. booked $8.1M in FY2022 revenue, contracting 41% year over year — slower than 79% of Healthcare companies we track, at a -2153.8% net margin.
Peers · Healthcare
MJardin Group, Inc.——Aspyra Inc.——Nuwellis, Inc.43DNextleaf Solutions Ltd.57CCoya Therapeutics, Inc.48DCogent Biosciences, Inc.48DNeighbors
Middlesex →Key facts
CEOAlexander G. Cumbo
SectorHealthcare
IndustryBiotechnology
HeadquartersCambridge, MA
ExchangeNASDAQ: SLDB
Employees121
IPO date2018-01-26
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.